Therapeutic strategies to slow chronic kidney disease progression

Elke Wühl, Franz Schaefer, Elke Wühl, Franz Schaefer

Abstract

Childhood chronic kidney disease commonly progresses toward end-stage renal failure, largely independent of the underlying disorder, once a critical impairment of renal function has occurred. Hypertension and proteinuria are the most important independent risk factors for renal disease progression. Therefore, current therapeutic strategies to prevent progression aim at controlling blood pressure and reducing urinary protein excretion. Renin-angiotensin-system (RAS) antagonists preserve kidney function not only by lowering blood pressure but also by their antiproteinuric, antifibrotic, and anti-inflammatory properties. Intensified blood pressure control, probably aiming for a target blood pressure below the 75th percentile, may exert additional renoprotective effects. Other factors contributing in a multifactorial manner to renal disease progression include dyslipidemia, anemia, and disorders of mineral metabolism. Measures to preserve renal function should therefore also comprise the maintenance of hemoglobin, serum lipid, and calcium-phosphorus ion product levels in the normal range.

Figures

Fig. 1
Fig. 1
Pathophysiology, consequences, and treatment options of hypertension and proteinuria in chronic kidney disease. EPO erythropoietin, P reduction serum phosphate reduction, RAS renin angiotensin system, Non-DHP CCP non dihydropyridine calcium channel blockers, TGFβ transforming growth factor β, TIMP tissue inhibitors of metalloproteinases, ET1 endothelin 1, PAI plasminogen activator inhibitor, ⊥ inhibitory effect

References

    1. Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F. Epidemiology of chronic renal failure in children: data from the ItalKid Project. Pediatrics. 2003;111:382–387.
    1. González Celedón C, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol. 2007;7:1014–20.
    1. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. Hypertension. 1996;13:180–193.
    1. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–1474.
    1. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996;11:461–467.
    1. Seeman T, Simkova E, Kreisinger J, Vondrak K, Dusek J, Gilik J, Feber J, Dvorak P, Janda J. Control of hypertension in children after renal transplantation. Pediatr Transplant. 2006;10:316–322.
    1. Lingens N, Dobos E, Witte K, Busch C, Lemmer B, Klaus G, Schärer K. Twenty-four-hour ambulatory blood pressure profiles in pediatric patients after renal transplantation. Pediatr Nephrol. 1997;11:23–26.
    1. Schaefer Franz, Mehls Otto. Pediatric Hypertension. Totowa, NJ: Humana Press; 2004. Hypertension in Chronic Kidney Disease; pp. 371–387.
    1. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European study group of nutritional treatment of chronic renal failure in childhood. Lancet. 1997;349:1117–1123.
    1. Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis. 2000;36:646–661.
    1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med. 1995;123:754–762.
    1. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342–351.
    1. Chobanian AV, Barkis GL, Black DL, Cushman WC, Green LA, Izzo JLJ, Jones DW, Materson BJ, Oparil S, Wright JTJ, Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA. 2003;289:2560–2571.
    1. Guidelines for the Management of Arterial Hypertension The task force of the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187.
    1. Kidney Disorder Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–S290.
    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576. doi: 10.1542/peds.114.2.S2.555.
    1. Wühl E, Mehls O, Schaefer F, ESCAPE trial group Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–776.
    1. Jacob P, Hartung R, Bohlender J, Stein G. Utility of 24-h ambulatory blood pressure measurement in a routine clinical setting of patients with chronic renal disease. J Hum Hypertens. 2004;18:745–751.
    1. Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E. ‘Non-dipper’ hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol. 1995;43:382–387.
    1. Tarver-Carr M, Brancati F, Eberhardt M, Powe N. Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol. 2000;11:168A.
    1. Hoy WE, Wang Z, vanBuynder P, Baker PR, Mathews JD. The natural history of renal disease in Autralian aborigines. Part I. Changes in albuminuria and glomerular filtration rate over time. Kidney Int. 2001;60:243–248.
    1. Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806–814.
    1. Risdon RA, Sloper JC, de Wardener HE. Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968;2:363–366.
    1. Remuzzi G, Ruggenenti P, Perico N. Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–615.
    1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter LJ. Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med. 1995;123:754–762.
    1. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN) Kidney Int Suppl. 1997;63:S54–S57.
    1. Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, Procaccio M, Avolio L, Ciofani A, Dello Strologo L, Montini G. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Pediatr Nephrol. 2004;19:172–177.
    1. Wühl E, Mehls O, Schaefer F, ESCAPE trial group Long-term dissociation of antiproteinuric and antihypertensive efficacy of ACE inhibition in children with chronic renal failure. Pediatr Nephrol. 2006;21:1505.
    1. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE) Pediatrics. 2000;105:1242–1249.
    1. Litwin M. Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol. 2004;19:178–186.
    1. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863. doi: 10.1016/S0140-6736(96)11445-8.
    1. Wright JT, Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. African American study of kidney disease and hypertension: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2003;288:2421–2431.
    1. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2–15.
    1. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int. 2003;63:2254–2261.
    1. Jafar TH, Schmid CH, Landa M, Giatras J, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, DeJong P, DeZeeuw D, Lau J, Levey AS, ACE inhibition in progressive renal disease study group Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.
    1. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601–1608.
    1. Muntner P, Coresh J, Clinton Smith J, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.
    1. Saland MJ, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr. 2002;14:197–204.
    1. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24:46–53.
    1. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl. 1999;71:S47–S50.
    1. Mulec H, Johnson SA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet. 1990;335:1537–1538.
    1. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–174.
    1. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806–816.
    1. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-ß1-independent mechanism. Kidney Int. 1997;52:637–647.
    1. Aydin Z, Duijs J, Bajerna IM, van Zonneveld AJ, Rabelink TJ. Erythropoietin, progenitors, and repair. Kidney Int. 2007;72:516–520.
    1. Karamouzis I, Sarafidis PA, Karamouzis M, Illiadis S, Haidich A-M, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol. 2008;28:397–404.
    1. Baudoin P, Provoost AP. Effects of age at the time of unilateral nephrectomy and dietary protein on long-term renal function in rats. Pediatr Nephrol. 1993;7:536–542.
    1. Ritz E, Gross ML, Dikow R. Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int. 2005;68(Suppl 99):S66–S70.
    1. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of agressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–1097.
    1. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Sanpinn SM, Zhan Z, Shahinfar S, RENAAL study investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
    1. Lewis EJ, Hunsicker LG, Raymond PB, Rohde RD, Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462.
    1. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of antiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16:3631–3641.
    1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945.
    1. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175–1179.
    1. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R. Long-term comparison between captopril and nifidepine in the progression of renal insufficiency. Kidney Int. 1992;42:452–458.
    1. Kamper AL, Strandgaard S, Leyssac P. Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens. 1992;5:423–430.
    1. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl. 1997;63:S58–S62.
    1. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM, Grunfeld JP. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833–837.
    1. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. 1995;111:184–192.
    1. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting-enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996;27:489–495.
    1. Ruggenenti P, Perna A, Gherardi G, Garini G, Zocalli C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364.
    1. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European microalbuminuria captopril study group. JAMA. 1994;271:275–279.
    1. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ. 1988;297:1086–1091.
    1. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117—124.
    1. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics exposed to telmisartan and enalapril study group Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–1961.
    1. Casas JP, Weiliang C, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033.
    1. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990;15:276–282.
    1. van den Meiracker AH, Man in’t Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalenkamp MA. Partial escape of agiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803–812.
    1. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis. 2001;37:477–483.
    1. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003;14:3217–3232.
    1. Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol. 2004;19:688–690.
    1. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr. 2003;143:89–97.
    1. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int. 2004;46:576–579.
    1. Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, la Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM, ItalKid project No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy-report from the ItalKid Project database. Nephrol Dial Transplant. 2007;22:2525–2530.
    1. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92:38–42.
    1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
    1. The Randomized Aldactone Evaluation Study (RALES) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol. 1996;78:902–907.
    1. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006;29:211–216.
    1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370:221–229.
    1. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–1951.
    1. Kumagai H, Hayashi K, Kumamaru H, Saruta T. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: A one-year, prospective, randomized study. Am J Hypertens. 2000;13:980–985.
    1. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12:212–221.
    1. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicenter randomized study. Int J Clin Pract. 1999;53:519–522.
    1. Doulton TW, He FJ, MacGregor FA. Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45:880–886.
    1. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094–1103.
    1. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20.
    1. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–1025.
    1. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–3045.
    1. Hermida RC, Diana EA, Calvo C. Administration-time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr Opin Nephrol Hypertens. 2005;14:453–459.
    1. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:e28–e32.
    1. Hermida RC, Calvo C, Ayala DE, Lopez JE. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension. 2005;46:960–968.
    1. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998;53:1353–1357.
    1. Mak RH. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol. 1998;12:660–665.
    1. Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int. 1998;54:603–607.
    1. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41. 2003;Suppl 3:S1–S91.
    1. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double -blind, randomized trials. Int J Cardiol. 2007;117:64–74.
    1. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German study group for growth hormone treatment in chronic renal failure Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248.
    1. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2–14.
    1. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635–1645.
    1. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016.
    1. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Shaeff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115–2124.
    1. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007;72:455–463.
    1. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753–760.
    1. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
    1. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, Collins AJ, Kopple JD. Effect of dietary protein restriction on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006;48:876–888.
    1. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Cochrane Database Syst Rev. 2000;2:CD001892.
    1. Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev. 2007;4:CD006863.
    1. Klahr S, Levy AD, Beck GJ. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–884.
    1. National Kidney Foundation K/DOQI Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2003;46(Suppl 1):S12–S100.
    1. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–238.
    1. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qui P, Williams L, Batlle W. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–2828.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner